Analysis of ETAR (ETAR-positive; DCIS: 67.9% vs IBC: 65.5% of cases), VEGF-C (VEGF-C positive; DCIS: 80.4% vs IBC: 88.6%), Flt-4 (Flt-4 positive; DCIS: 92.3% vs IBC: 93.3%), and Her-2/neu (Her-2/neu positive; DCIS: 21.9% vs IBC: 16.4%) expression revealed a similar frequency of positive staining in the in situ and the invasive carcinomas. This evidence concerns the gene ERBB2 and invasive carcinoma.